Onconetix Net Worth
Onconetix Net Worth Breakdown | ONCO |
Onconetix Net Worth Analysis
Onconetix's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Onconetix's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Onconetix's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Onconetix's net worth analysis. One common approach is to calculate Onconetix's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Onconetix's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Onconetix's net worth. This approach calculates the present value of Onconetix's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Onconetix's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Onconetix's net worth. This involves comparing Onconetix's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Onconetix's net worth relative to its peers.
To determine if Onconetix is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Onconetix's net worth research are outlined below:
| Onconetix generated a negative expected return over the last 90 days | |
| Onconetix has high historical volatility and very poor performance | |
| Onconetix has some characteristics of a very speculative penny stock | |
| Onconetix has a very high chance of going through financial distress in the upcoming years | |
| Onconetix was previously known as BWV and was traded on NASDAQ Exchange under the symbol BWV. | |
| Onconetix currently holds 9.89 M in liabilities. Onconetix has a current ratio of 0.61, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Onconetix's use of debt, we should always consider it together with its cash and equity. | |
| The entity reported the previous year's revenue of 58.47 K. Net Loss for the year was (37.41 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Onconetix currently holds about 113.36 K in cash with (13.58 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.85, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Onconetix has a frail financial position based on the latest SEC disclosures | |
| Roughly 58.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from MacroaxisInsider: Insider Trading |
Onconetix uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Onconetix. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Onconetix's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 14th of March 2024 Upcoming Quarterly Report | View | |
| 10th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 14th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Follow Onconetix's market capitalization trends
The company currently falls under 'Nano-Cap' category with a current market capitalization of 9.04 M.Market Cap |
|
Project Onconetix's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (4.84) | (4.59) | |
| Return On Capital Employed | (0.50) | (0.53) | |
| Return On Assets | (0.42) | (0.44) | |
| Return On Equity | (0.64) | (0.67) |
When accessing Onconetix's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Onconetix's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Onconetix's profitability and make more informed investment decisions.
Evaluate Onconetix's management efficiency
Onconetix has return on total asset (ROA) of (0.2185) % which means that it has lost $0.2185 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (17.5848) %, meaning that it created substantial loss on money invested by shareholders. Onconetix's management efficiency ratios could be used to measure how well Onconetix manages its routine affairs as well as how well it operates its assets and liabilities. As of the 26th of November 2024, Return On Tangible Assets is likely to grow to -4.59. In addition to that, Return On Capital Employed is likely to drop to -0.53. At this time, Onconetix's Total Assets are very stable compared to the past year. As of the 26th of November 2024, Non Current Assets Total is likely to grow to about 87.1 M, while Other Assets are likely to drop 0.80.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 3.84 | 4.03 | |
| Tangible Book Value Per Share | (0.90) | (0.86) | |
| Enterprise Value Over EBITDA | (3.84) | (4.03) | |
| Price Book Value Ratio | 2.31 | 2.20 | |
| Enterprise Value Multiple | (3.84) | (4.03) | |
| Price Fair Value | 2.31 | 2.20 | |
| Enterprise Value | 126.8 M | 112.7 M |
Onconetix showcases strong leadership that adapts to market changes and drives innovation. Our analysis explores how this adaptability affects the stock's investment appeal.
Enterprise Value Revenue 15.979 | Revenue 1.5 M | Revenue Per Share 2.892 | Return On Equity (17.58) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Onconetix insiders, such as employees or executives, is commonly permitted as long as it does not rely on Onconetix's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Onconetix insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Altos Venture Ag a day ago Insider Trading | ||
Altos Venture Ag 2 days ago Insider Trading | ||
Altos Venture Ag 3 days ago Insider Trading | ||
Altos Venture Ag few days ago Insider Trading | ||
Altos Venture Ag few days ago Insider Trading | ||
Altos Venture Ag few days ago Insider Trading | ||
Altos Venture Ag six days ago Insider Trading | ||
Altos Venture Ag over a week ago Insider Trading | ||
Altos Venture Ag over a week ago Insider Trading | ||
Altos Venture Ag over a week ago Insider Trading | ||
Altos Venture Ag over a week ago Insider Trading | ||
Altos Venture Ag over a week ago Insider Trading |
Onconetix Earnings per Share Projection vs Actual
Onconetix Corporate Management
| MD MBA | Chief Officer | Profile | |
| Christian Bruhlmann | Chief Officer | Profile | |
| Dr Very | Senior Development | Profile | |
| Theodore Yoho | Head Development | Profile | |
| Erin Henderson | Consultant | Profile | |
| Brian Price | Head Strategy | Profile | |
| Ali Fattom | Head Discovery | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Onconetix. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. To learn how to invest in Onconetix Stock, please use our How to Invest in Onconetix guide.You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Onconetix. If investors know Onconetix will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Onconetix listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (109.20) | Revenue Per Share 2.892 | Return On Assets (0.22) | Return On Equity (17.58) |
The market value of Onconetix is measured differently than its book value, which is the value of Onconetix that is recorded on the company's balance sheet. Investors also form their own opinion of Onconetix's value that differs from its market value or its book value, called intrinsic value, which is Onconetix's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Onconetix's market value can be influenced by many factors that don't directly affect Onconetix's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Onconetix's value and its price as these two are different measures arrived at by different means. Investors typically determine if Onconetix is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Onconetix's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.